TABLE 2: Clinical and laboratory manifestations of the cryptococcal disease according to the C. neoformans/C. gattii species complex.
| C. gattii complex | C. neoformans | Total | P value* | |
|---|---|---|---|---|
| n/% | n/% | n/% | ||
| Clinical Manifestation | ||||
| Meningitis | 7/58 | 15/63 | 22/61 | 1.0 |
| Brain granuloma or pseudocyst | 3/25 | 1/4 | 4/11 | 0.0980 |
| Cryptococcemia | 0/0 | 9/38 | 9/25 | 0.0163 |
| Pulmonary lesion | 8/67 | 9/38 | 17/47 | 0.1582 |
| Cutaneous lesion | 3/25 | 3/13 | 6/17 | 0.3781 |
| Lymphadenopathy | 1/8 | 0/0 | 1/3 | 0.3333 |
| CSF alterations | (n=7) | (n=15) | (n=22) | |
| Cells - no./µL - mean ± SD | 100.42 ± 11.99 | 115.73 ± 236.80 | 110.8 ± 80.05 | 0.6867 |
| Protein - mg/dL - mean ± SD | 161.28 ± 236.80 | 144.42 ± 182.22 | 150± 196.1 | 0.8582 |
| Glucose - mg/dL - mean ± SD | 45.85± 45.38 | 30.28 ± 24.05 | 35.4 ± 32,4 | 0.3115 |
| Cryptococcal antigen titera - median ange) | ≥ 4096 | 3072 | ≥4096 | 0.4714 |
| (64 - ≥ 4096) | (NR - ≥ 4096) | (NR - ≥ 4096) | ||
| Antibodies anti-Cryptococcus in serumb | ||||
| Reactive patients / total | 7;11/64 | 4;16/25 | 11;27/41 | 0.0608 |
| Antibodies titer - median (range) | 8 (1 - 16) | 2.5 (1 - 8) | 4 (1 - 16) | 0.0264 |
| Patients - Total | 12/100 | 24/100 | 36/100 |
a) Latex agglutination test: titer-inverse of CSF dilution; b) counterimmunoelectrophoresis test: titer-inverse of serum dilution; *statistical analysis; SD: standard deviation; CSF: cerebrospinal fluid; NR: non-reactive.